Why Didn't My Doctor Recommend — Targeted Therapy for Me?

No. Eligibility for targeted therapy is about your tumour's molecular profile, not about how advanced or difficult your cancer is. Some early-stage cancers do not carry targetable mutations. Some advanced cancers do. The two questions are entirely separate. Your oncologist can explain your stage and your treatment options as two distinct pieces of information — do not assume that ineligibility for one type of treatment says anything about your outlook overall.

Biomarker testing on your tumour tissue makes the determination. The laboratory analyses a sample from your biopsy and looks for specific genetic changes — mutations, gene fusions, amplifications, or changes in protein expression — that targeted drugs are designed to act on. Which markers are tested depends on your cancer type. Results typically take one to two weeks. If your original biopsy sample was too small, a repeat biopsy may be needed before the question can be properly answered.

Laboratory testing is validated and reliable, but borderline results — where a marker is present at a very low level — can be genuinely uncertain. If you have reason to doubt the result, ask your oncologist whether the sample was adequate in size and quality, and whether a validated assay was used. Requesting a second opinion from another institution is reasonable when the result will determine your entire treatment course. Your oncologist should be able to explain the confidence level of the finding.

You can ask, and your oncologist will take the question seriously. The honest answer is that targeted drugs carry real side effects, and those risks are only worth taking where there is a biological basis for expecting benefit. Without the mutation the drug targets, that basis is absent. Paying privately does not change the biology of your tumour. If you want certainty, a second opinion from another oncologist is a more useful step than insisting on a treatment the evidence does not support for your tumour.

Usually, yes. Tumours can change their molecular characteristics over time, particularly at relapse, and a mutation that was absent at diagnosis may appear later. A new biopsy may also reveal biology that the original sample missed. If your cancer recurs or progresses, ask your oncologist whether retesting is appropriate. New targeted therapies are also approved steadily, so a result from a few years ago may not reflect what options exist today.

This depends on your specific cancer type and the mutations present in your tumour. CDSCO approves targeted therapies for specific indications, meaning a drug approved for one cancer is not automatically appropriate for another, even if the names sound similar. Ask your oncologist directly which targeted agents, if any, are approved for your cancer type in India, and what biomarker results are required for each. Do not go by what someone with a different cancer type was prescribed.

The alternative depends on your cancer type, stage, general health, and what your tumour's biology suggests will be effective. For many patients it is chemotherapy, hormone therapy, immunotherapy, radiation, or a combination of these. Some patients receive two or more in sequence. Ask your oncologist to explain the recommended plan and what each component aims to achieve. Ask also what a response to treatment looks like for your situation, so you have a clear picture of what the team will be watching for.

Possibly. Clinical trials sometimes include patients whose tumours show mutations at low levels, or who have cancer types not yet covered by approved indications for a given drug. Trials are not a last resort — for some patients they are a well-matched option at the right stage. Ask your oncologist whether any open trials are relevant to your tumour profile. CION oncologists are connected to research networks and can advise on whether a trial is worth exploring for your situation.